Cala Health, a spinout from Stanford Biodesign, is founded in Silicon Valley to treat movement disorders with novel non-invasive technology.
We’re building innovative therapies that profoundly impact people’s lives.
About Cala
At Cala, we’re working to free people from the burden of chronic disease. We began by creating the first non-invasive prescription therapy for hand tremor. After years of careful fine-tuning and improvements, we released Cala kIQ — our most sophisticated therapy yet. Our products have empowered thousands of people to get back to their lives with confidence and ease.
But we won’t stop there. Our pioneering technology can be applied across neurology, cardiology, and so much more. It’s all part of our mission to help people in their struggle with chronic disease. We’re only just getting started.
Stacy Enxing Seng
Chairwoman of the Board
James Lee
Board Director
Jordi Parramon
Board Director
Juan-Pablo Mas
Board Director
Mike Carusi
Board Director
John Kuelper
Board Director
Neil Tiwari
Board Director
Deanna Harshbarger
Chief Executive Officer
Kate Rosenbluth, PhD
President & Chief Innovation Officer
The story so far
Cala completes ET-03, a multi-center, randomized, controlled trial to assess the safety and effectiveness of Cala TAPS™ therapy to aid in the symptomatic relief of hand tremors.
Cala One therapy receives de novo clearance by the FDA for temporary relief of hand tremors in adults with ET.
Cala completes the PROSPECT study: Prospective Study for Symptomatic Relief of Essential Tremor with Cala Therapy, the largest noninvasive therapeutic clinical research study ever conducted for treatment of essential tremor. The study demonstrated that Cala TAPS therapy, repeatedly used at home over three months, resulted in safe and effective hand tremor reduction and improved quality-of-life for adults with ET.
Cala Health receives FDA Breakthrough Device Designation for Cala TAPS therapy to treat action tremors in Parkinson’s disease.
CMS creates unique HCPCS codes for Cala TAPS therapy, facilitating a path to healthcare claims processing for TAPS therapy.
Publication of the first retrospective, long-term real world evidence of TAPS in the Journal of Tremor and Other Hyperkinetic Movements.
Cala launches the next generation device to deliver TAPS therapy, the Cala kIQ™ system, is introduced.
Cala receives positive Medicare Local Coverage Determination for TAPS therapy for essential tremor (ET) from the Centers for Medicare & Medicaid Services (CMS): External Upper Limb Tremor Stimulator Therapy L39591.
Cala Health is powering the age of bioelectronic medicine and propelling a paradigm shift in healthcare. The combination of our unique approach and the multitude of applications of TAPS provide opportunities to make a difference in the lives of people living with many different diseases, both now and in the future.
Solving Diagnostic Dilemmas: How a Skin-Based Test for Synucleinopathies Can Change the Treatment Course for Patients Presenting with Tremors
See yourself working here?
Join our mission to set a new standard of care for chronic disease.